Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
+1 212 318 2000
Europe, Middle East, & Africa
+44 20 7330 7500
+65 6212 1000
Generic drug maker Mylan Inc. said Tuesday it obtained a federal court order blocking a competing version of its antidepressant Paxil from the U.S. market.
The company said the District Court for the District of New Jersey has prohibited Canadian drug maker Apotex from selling or shipping versions of the pill, which was originally marketed by GlaxoSmithKline.
The court has scheduled further hearings on the issue for Oct. 18, the company said in a statement.
The order also prohibits British drug maker GlaxoSmithKline from supplying Apotex with a generic version of the product, the company said.
Mylan has marketed generic Paxil in the U.S. since 2008. It was the first generic drug maker to file an application for the drug with the Food and Drug Administration.